Hosted on MSN1mon
Nuvig secures $161m financing to support clinical studies for NVG-2089
Nuvig Therapeutics has closed a $161m Series B financing round to advance its preclinical pipeline and support NVG-2089’s clinical proof-of-concept trials. The first-in-class recombinant Fc ...
MedCity News1mon
Nuvig Therapeutics Nabs $161M to Build Case for a Better Approach to Autoimmune Disease
Nuvig Therapeutics is developing a first-in-class drug that could offer an alternative treatment for autoimmune diseases and the startup now has $161 million to advance clinical development of its ...
Business Wire1mon
Nuvig Therapeutics Announces $161 Million Series B Financing and Progression to Phase 2 Development with Novel, Second-Generation Immunomodulator
MENLO PARK, Calif.--(BUSINESS WIRE)--Nuvig Therapeutics, Inc., (“Nuvig”) a privately held biotechnology company developing novel immunomodulatory therapeutics for patients with inflammatory ...
pharmaphorum5d
Atlas closes $450m biotech fund, and other financing news
Nuvig, Maze, and Antag close funding rounds In other financing news this week, immunomodulation therapy developer Nuvig Therapeutics has completed a $161 million second-round financing that will ...
Morningstar1mon
Nuvig Therapeutics Announces $161 Million Series B Financing and Progression to Phase 2 Development with Novel, Second-Generation Immunomodulator
Morningstar brands and products Company Portfolio ...